(TILS) – Globe Newswire
-
Tiziana Life Sciences - Scheme Effective Date
-
Tiziana Life Sciences plc: PDMR Dealing
-
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
-
Tiziana Life Sciences plc: PDMR Dealing
-
Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting
-
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021
-
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Canc
-
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
-
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand
-
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in t
-
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to
-
Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021
-
Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited
-
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today
-
Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting
-
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Mono
-
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
-
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
-
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
-
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers
-
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Anti
-
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
-
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Ad
-
Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
-
Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.
-
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Und
-
Tiziana Life Sciences plc: Accustem Update
-
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
-
Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today
-
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
-
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
-
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
-
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
-
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
-
Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
-
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
-
Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
-
Tiziana Life Sciences to Present at Biotech Showcase Digital 2021
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD
-
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus
-
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM
-
Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
-
Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing
-
Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease
-
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
-
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
Back to TILS Stock Lookup
